AVO.L Regulatory News (AVO)

22 December 2016

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Further progress in the technical development of the LIGHT system

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has integrated the proton source and Radio Frequency Quadruple (RFQ), following a successful testing and calibration programme at ADAM, in Geneva.

This work has demonstrated there is a predicted acceleration of the proton beam through this very sophisticated structure, the RFQ, and that the measurements matched those expected from computer simulations. The completion of this key milestone is a significant indicator of the continued successful technical development of the Company's LIGHT proton system.

Advanced Oncotherapy's Professor Steve Myers, Executive Chairman of ADAM and previously Director of Accelerators and Technology at CERN and Head of CERN Medical Applications, stressed the significance of designing and building an RFQ with notably higher frequency and, hence, shorter wavelength and smaller dimensions than current comparable linear accelerators.

In the video recently made available on the Company's website, Paul Collier, Head of Beams Department at CERN, spoke about the unique features of AVO's LIGHT system's RFQ, which has been designed and built by CERN:

"This high frequency RFQ is the most beautiful piece of equipment I have been involved in manufacturing. This is a very important piece of technology transfer from CERN to the outside world. We were challenged to design and build the world's highest frequency and highest power RFQ."

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.